Although IFN-γ inhibition would commonly be employed as a bridge to allogeneic stem cell transplantation, the successful use of emapalumab was also reported after transplant rejection in three relapsed primary HLH patients [45,46]. Here, IFNG is linked to hemophagocytic syndrome.